Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 78

recruiting
3 975
countries
28
conditions
2 106

1 514 trials match your criteria

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Cardiogenic shock

Not recruiting

Study on Istaroxime for Patients with Cardiogenic Shock Stage C

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Istaroxime

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Frexalimab

Study of Sotatercept for People with Pulmonary Arterial Hypertension

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept

Cardiac amyloidosis

Not recruiting

Study of Patisiran for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Patisiran

Colitis ulcerative

Not recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Tolebrutinib

Giant cell arteritis

Not recruiting

Study of secukinumab and prednisone combination therapy for patients with giant cell arteritis (GCA): Evaluation of treatment effectiveness and safety

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone

Study of Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.